Eighth International Congress on Drug Therapy in HIV Infection Glasgow, UK - 12-16 November 2006

Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL12.1

Judith Currier
University of California, Los Angeles, USA

PURPOSE OF THE STUDY: Data from observational studies suggest that HIV infection, and to some extent HIV treatments, may contribute to increasing cardiovascular risk. Although the specific contributions of traditional risk factors and HIV therapy to cardiovascular risk remain incompletely defined, it is critical that providers determine the optimal means to reduce long-term cardiovascular risk in this population. This presentation will review current knowledge on the success of interventions designed to reduce both types of risk factors for cardiovascular risk in the HIV population. Randomized and observational studies of lipid-lowering agents and strategies to reduce cardiovascular risk markers through changes in antiretroviral therapy will be reviewed. In addition, key areas for future research in this area will be highlighted.

Plenary Session: Adverse Events II

2006-11-12
PL12.1

Copyright © 2006 - Thomson ACUMED® All rights reserved. Thomson ACUMED® is an intelligent and innovative medical marketing and communications agency – a new division of The Gardiner-Caldwell Group Ltd, part of The Thomson Corporation, located in Tytherington, UK.

Reproduction of this abstract (other than one copy for personal reference) must be cleared through the authors.

This information is designed to support, not replace, the relationship that exists between you and your doctor. ©1980, 2006. AEGiS.